Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy - Summary - MDSpire

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

  • By

  • Konstantin E. Seifert

  • Hendrik Dinkel

  • Linda Huberth

  • Dorothee Tiedje

  • Jan Gröticke

  • Laura-Maria Krabbe

  • Frederike Tepel

  • Kambiz Rahbar

  • Christof Bernemann

  • Andres J. Schrader

  • Martin Bögemann

  • Martin Janssen

  • Katrin Schlack

  • Barbara Heitplatz

  • January 16, 2026

  • 0 min

Share

Objective:

To evaluate the pathological and radiographic response in patients with locally advanced renal cell carcinoma (RCC) who underwent neoadjuvant therapy and assess the safety and feasibility of surgical resection following preoperative systemic therapy.

Key Findings:
  • 17 patients included, mean age 65 years, predominantly clear cell histology (94.1%).
  • Mean size of primary renal tumor was 9.1 cm prior to systemic therapy.
  • Pathological and radiographic responses indicated significant tumor size reduction (specific metrics needed) and improved surgical feasibility.
Interpretation:

The study suggests that neoadjuvant systemic therapy can lead to meaningful tumor downstaging in locally advanced RCC, enhancing the potential for successful surgical intervention.

Limitations:
  • Small sample size of 17 patients limits generalizability and may affect the robustness of the findings.
  • Retrospective design may introduce selection bias.
Conclusion:

Neoadjuvant therapy appears to improve surgical outcomes in locally advanced RCC, warranting further investigation in larger, prospective studies to validate these findings.

Original Source(s)

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

  • by Konstantin E. Seifert, Hendrik Dinkel, Linda Huberth, Dorothee Tiedje, Jan Gröticke, Laura-Maria Krabbe, Frederike Tepel, Kambiz Rahbar, Christof Bernemann, Andres J. Schrader, Martin Bögemann, Martin Janssen, Katrin Schlack, Barbara Heitplatz

  • January 16, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026